An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10exp9/L to 100 x 10exp9/L.

Trial Profile

An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10exp9/L to 100 x 10exp9/L.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 07 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Sep 2020.
    • 14 May 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 06 Jan 2013 New source identified and integrated (Vanderbilt-Ingram Cancer Center record: VICCHEM1180).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top